Event

SITC 2020 - Agenus Presents 7 Novel Programs

November 9 - November 14, 2020

 

  • Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors - Case Report from Phase 2 Study (NCT03104699)
    Abstract number: 245
    Presenting author: Dr. Cesar Perez
    ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pm

  • AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy (NCT03860272)
    Abstract number: 398
    Presenting author: Dr. Stephen O’Day
    ePoster and audio session times: 11/12 4:50-5:20pm; 11/14 1:00-1:30pm

  • AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects
    Abstract number: 377
    Presenting author: Dr. Claire Galand
    ePoster and audio session times: 11/11 5:15-5:45; 11/13 4:40-5:10pm

  • Pseudoprogression Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer
    Abstract number: 267
    Presenting author: Dr. David O’Malley
    ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pm

  • AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing
    Abstract number: 164
    Presenting author: Dr. Burcu Yigit
    ePoster and audio session times: 11/12 4:50-5:20; 11/14 1:00-1:30pm

  • Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity
    Abstract number: 253
    Presenting author: Rebecca Ward
    ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pm

  • Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro
    Abstract number: 70
    Presenting author: Dr. Simarjot Pabla
    ePoster and audio session times: 11/12 4:50-5:20pm; 11/14 1:00-1:30pm